225 related articles for article (PubMed ID: 19194830)
1. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y
Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.
He M; Wang Y; Shi WJ; Wang SJ; Sha HF; Feng JX; Wang J
J Dig Dis; 2011 Oct; 12(5):393-400. PubMed ID: 21955433
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
4. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
5. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
[TBL] [Abstract][Full Text] [Related]
6. [Induction of dendritic cells from intra-operative lost blood and their effects on CIK against liver cancer cells in vitro].
DU Z; Zhao XL; Gao YT; Wu CX; Wang YJ; Zhu ZY; Sun Q; Fang SC
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):759-63. PubMed ID: 19173806
[TBL] [Abstract][Full Text] [Related]
7. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
8. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
9. [The functional mechanism of CIK cells on ovarian carcinoma cell lines SKOV3/CDDP].
Zhang H; Zhao Q; Zuo LF; Ma HJ; Li SR; Cheng JX; Jia JH; Kang S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1167-9. PubMed ID: 18062892
[TBL] [Abstract][Full Text] [Related]
10. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
11. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
12. [The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia].
Li Y; Huang SL; Zhang XC; Fang JP; Wu YF; Wei J; Huang WG; Zhou DH; Huang K; Lin YC
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):39-43. PubMed ID: 18512314
[TBL] [Abstract][Full Text] [Related]
13. [Proliferation and cytotoxicity of RetroNectin-activated cytokine-induced killer cells against cisplatin-resistant lung carcinoma cell].
Ren W; Wang Z
Sheng Wu Gong Cheng Xue Bao; 2008 Aug; 24(8):1373-80. PubMed ID: 18998538
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
[TBL] [Abstract][Full Text] [Related]
15. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
16. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice.
Wongkajornsilp A; Somchitprasert T; Butraporn R; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Maneechotesuwan K; Hongeng S
Cancer Invest; 2009 Feb; 27(2):140-8. PubMed ID: 19235585
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
18. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells.
Zhu XL; Lin ZB
Acta Pharmacol Sin; 2005 Sep; 26(9):1130-7. PubMed ID: 16115382
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA.
Li HF; Yang YH; Shi YJ; Wang YQ; Zhu P
Chin Med J (Engl); 2004 Sep; 117(9):1348-52. PubMed ID: 15377427
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
